Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

But the results add to evidence from animal studies and reports that people are finding drugs like Ozempic and Wegovy helpful ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age. Cheng-Han Chen ...